Profile
Andreas Seidl currently works at Formycon AG, as Chief Scientific Officer from 2022.
Dr. Seidl also formerly worked at LEUKOCARE AG, as Chief Operating Officer from 2019 to 2022, Hexal Biotech GmbH, as Head-Analytics & Quality Control from 2002 to 2010, and Novartis AG, as Site Manager from 2010 to 2015.
Dr. Seidl received his doctorate degree from Universität Konstanz.
Andreas Seidl active positions
| Companies | Position | Start |
|---|---|---|
| FORMYCON AG | Chief Tech/Sci/R&D Officer | 01/07/2022 |
Former positions of Andreas Seidl
| Companies | Position | End |
|---|---|---|
LEUKOCARE AG
LEUKOCARE AG Medical/Nursing ServicesHealth Services Develops protein stabilization and protection solutions | Chief Operating Officer | 01/01/2022 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2015 |
Training of Andreas Seidl
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Universität Konstanz
Universität Konstanz Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LEUKOCARE AG
LEUKOCARE AG Medical/Nursing ServicesHealth Services Develops protein stabilization and protection solutions | Health Services |
Formycon AG
Formycon AG Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
- Stock Market
- Insiders
- Andreas Seidl
















